Nitric Oxide Releasing Solution (NORS) For The Treatment Of Human Papillomavirus(HPV) Verrucae Plantaris (Plantar Warts)

Summary

A phase 2a multicenter, randomized, double-blinded, placebo-controlled clinical trial to evaluate the safety and efficacy of topical nitric oxide releasing solution (NORS) for the treatment of human papillomavirus (HPV) caused verrucae plantaris (plantar warts). Participants will be treated over a 21 day period with a final evaluation on Day 35. They will be separated into 3 treatment groups (placebo, 1x and 2x dose). Participants will be evaluated for change in wart size, wart clearance, and HPV genotype.

Timeline

Start

2023-08-02

Primary completion

2024-02-01

Completion

2024-04-12

Publications

• Schumacher SA, Dugom L, Martins J, Leemhuis J, Teskey SJL, Moore K, Miller CC. Efficacy and safety of a topical nitric oxide-releasing solution (NORS) as a noninvasive treatment for plantar warts (verrucae plantaris). J Dermatolog Treat. 2026 Dec;37(1):2610918. doi: 10.1080/09546634.2025.2610918. Epub 2026 Jan 6.

Drugs

Indications